Home Meetings Directions About Us Sponsors Mailing List Links

SCDMDG presents:

Human Microbiome and Metabolome Dynamics

Tuesday May 30, 2017
Rob Knight, Ph.D.
Founding Director, Center for Microbiome Innovation,
Jacobs School of Engineering with the School of Medicine
Professor, Department of Pediatrics
Professor, Department of Computer Science
University of California San Diego

Rob Knight, Ph.D.
(photo credit David Ahntholz)

About The Meeting

Advances in technology allow us to understand the human microbiota not as a static entity but as a complex, changing ecosystem that records substantial data about our lifestyles, our environmental exposures, and the people we live with. Here I discuss changes in the human microbiota associated with early life events such as delivery mode and antibiotics, the subsequent development of the microbiome throughout life, and even the development of the microbiome after death and its potential utility for forensics. Of particular value for toxicological studies is the ability to transfer the microbiome to germ-free mice, allowing individualized tests of function and subsequent therapies to be tested in personalized rodent models. Relating human to rodent microbiome timescales, especially for dietary studies, and relating multi-omics data in a timeseries context, remain outstanding challenges. Rapid progress is being made in these areas, and will allow far more powerful studies of the effects of drugs in mammalian hosts and our ability to stratify responders from non-responders for a wide range of therapies.

Date:   Tuesday May 30, 2017 – 5:00 p.m. (Appetizers), 6:00 p.m. (Buffet Dinner), 7:00 p.m. (Presentation)
Location:   National University, North Building
11355 North Torrey Pines Road
North Building
La Jolla, CA 92037
Price:   $20 Registration in advance or at the door (includes appetizers, buffet dinner and beverages)

Space is Limited — Register Early to Guarantee Your Attendance!

Click here for a printable flyer.

Our Spring 2017 meeting is generously sponsored by:

Silver Sponsors

Q2 Solutions
Q2 Solutions
Sekisui Xenotech
Sekisui Xenotech

Bronze Sponsors

National University

National University

For more information on sponsoring our May meeting, please refer to our sponsorship guidelines.

Prior presentations:

Note: slides are displayed in a new window, left-click to advance, right-click to go back.

Speaker PDF Topic Date
Kim L. R. Brouwer, Pharm.D., Ph.D.   Altered Disposition of Drugs and Bile Acids in Patients with Non-Alcoholic Steatohepatitis (NASH) December 7, 2016
Les Benet, Ph.D. The Use of BDDCS in Drug Development: The Observations, The Predictions, Understanding the Scientific Basis and The Extensions April 19, 2016
Nicholas J. Schork, Ph.D.   Design and Implementation Issues in Clinical Trials Advancing Personalized Medicine September 15, 2015
Robert P. Hanzlik, Ph.D.   Reactive Metabolites, Cellular Targets and Beyond April 28, 2015
J. Ernest Simpson, Ph.D.   The Chemistry Of Wine October 28, 2014
Lawrence J. Marnett, Ph.D., F.C.P   Next Generation NSAIDs That Selectively Inhibit Endocannabinoid Metabolism by COX-2 May 6, 2014
Lawrence J. Lesko, Ph.D., F.C.P. Drug Interaction Studies: Differences and Similarities in How to Meet the Regulatory Expectations in FDA Guidance and EMA Guidelines May 14, 2013
Thomas Tozer, Ph.D.
Pharmacokinetics of Protein Drugs October 23, 2012
Shujuan Chen Application of Animal Models for Human Glucuronidation October 23, 2012
Caroline Decker The Use of Modified Bacterial CYPs for Metabolite Generation October 23, 2012
Mary Dwyer, Ph.D. Cancer Therapeutics: A Novel Approach October 23, 2012
Justin Hoffman PharmD MS Population Pharmacokinetics (PK) of LopinavirDuring Pregnancy and Postpartum October 23, 2012
David A. Yee Observations on the Urine Metabolic Ratio of Oxymorphone to Oxycodone in Pain Patients October 23, 2012
Nabil Hanna, Ph.D.   The Discovery and Development of Rituxan April 10, 2012
Dr. Richard Kim Drug Transporters: In Vitro and Knockout Model Systems, Pharmacogenomics, and Clinical Relevance April 19, 2011
Dr. Jerry Galluppi Biotherapeutic Drug Research and Development: A Growing Role for the DMPK Scientist October 5, 2010
Dr. Dennis Smith Does drug metabolism hold its future in its own hands? April 27, 2010
Dr. Paul F. Hollenberg Mechanism-Based Inactivation of Human Cytochromes P450 October 6, 2009
Dr. Jack H. Dean
Dr. Thomas Baillie
  Challenges & Opportunities in Drug Development from a Drug Safety and Metabolism Perspective May 19, 2009
Eric Johnson, Ph.D.   Characterization of Substrate/Inhibitor Binding to Drug-Metabolizing Cytochrome P450 Monooxygenases using X-ray Crystallography September 30, 2008
Dr. Kenneth E. Thummel, Ph.D.   Regulation Of Intestinal CYP3A By VDR: Implications And Safety Of Oral Therapeutics May 7, 2008
Dr. Anthony Lu, Ph.D.   Why Is The Liver Microsomal Cytochrome P450 Such A Versatile And Unique Enzyme? September 12, 2007
Dr. Scott Obach, Ph.D.   Leveraging ADME Data In Metabolites In Safety Testing (MIST) April 18, 2007
Dr. Sidney Nelson, Ph.D.   Drug Metabolism and Chemical Structural Alerts September 27, 2006
Richard B. Kim, MD   Relevance and Utility of Transporters to Drug Discovery and Development September 21, 2005
Dr. Frederick P. Guengerich, Ph.D.   Human Cytochrome P450 2A6 as a Case History:  Flavors, Smoke, Blue Roses, New Drugs & Basics of a P450 April 27, 2005
Dr. Leslie Benet, Ph.D.   Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and BDDCS September 29, 2004
Dr. Christopher A. Lipinski, Ph.D.   ADME/Tox: How Low Can You Go And How Do You Recover? April 21, 2004